Search | Clinical Trials Finder

Conditions: Healthy
Interventions: PF-07976016, Placebo, Midazolam; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 117 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Peanut Allergies
Interventions: MY006 Low Dose, MY006 Mid Dose, MY006 High Dose, MY006 Selected Dose, Placebo (Vehicle); Drug
Lead sponsor: Mabylon AG; Industry
Eligibility: 12 Years to 55 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 9
States / cities: Little Rock, Arkansas • Aurora, Colorado • Colorado Springs, Colorado + 6 more

Conditions: Solid Tumors
Interventions: AZD6094 200 mg, Placebo, Moxifloxacin; Drug · Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Coccidioidomycosis
Interventions: Placebo, VT-1598; Other · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 45 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Severe Sepsis
Interventions: AZD9773 (CytoFab), Placebo; Drug · Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 26
States / cities: Birmingham, Alabama • Newark, Delaware • Bay Pines, Florida + 23 more

Conditions: Atherosclerosis, Cardiovascular Disease
Interventions: MEDI6570, Placebo, Part B Placebo; Biological
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 9
States / cities: Anniston, Alabama • Jacksonville, Florida • Miami, Florida + 6 more

Conditions: Healthy
Interventions: PRA052, Placebo; Drug · Other
Lead sponsor: Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 18 Years to 60 Years
Enrollment: 96 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Postoperative Pain
Interventions: HTX-011, Saline Placebo, Bupivicaine HCl, Ropivacaine; Drug
Lead sponsor: Heron Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 285 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 24
States / cities: Mobile, Alabama • Sheffield, Alabama • Phoenix, Arizona + 13 more

Conditions: Non-Small Cell Lung Cancer
Interventions: Erlotinib + Sorafenib, Erlotinib + Placebo; Drug
Lead sponsor: SCRI Development Innovations, LLC; Other
Eligibility: 18 Years and older
Enrollment: 166 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 16
States / cities: Fort Myers, Florida • Gainesville, Georgia • Marietta, Georgia + 13 more

Conditions: Carcinoma, Ovarian Epithelial, Ovarian Neoplasms, Ovarian Cancer, Ovarian Serous Adenocarcinoma, Fallopian Tube Neoplasms, Fallopian Tube Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Peritoneal Cancer, Peritoneal Carcinoma, Peritoneal Neoplasms
Interventions: Oregovomab, Paclitaxel, Carboplatin, Placebo; Biological · Drug
Lead sponsor: CanariaBio Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 615 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2028
U.S. locations: 81
States / cities: Phoenix, Arizona • Tucson, Arizona • Concord, California + 70 more

Conditions: Pulmonary Arterial Hypertension, Hypertension, Pulmonary
Interventions: Frespaciguat, Placebo to Frespaciguat; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 168 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 26
States / cities: La Jolla, California • Sacramento, California • San Francisco, California + 22 more

Conditions: Healthy Subjects
Interventions: STP707; Drug
Lead sponsor: Sirnaomics; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Inflammation, Systemic Lupus Erythematosus
Interventions: NNC 0151-0000-0000, placebo; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 1
States / cities: Lake Success, New York

Conditions: Heart Failure
Interventions: CXL-1020, Placebo for CXL-1020 Cohort 1, Placebo for CXL-1020 Cohort 2, CXL-1020 Dose for Echo Cohort A, CXL-1020 Doses for Echo Cohort B; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Tustin, California

Conditions: Covid19-associated ARDS, Covid19, ARDS
Interventions: AV-001, Placebo; Drug · Other
Lead sponsor: Vasomune Therapeutics, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Idiopathic Pulmonary Fibrosis, Systemic Sclerosis With Lung Involvement
Interventions: Vixarelimab, Placebo; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 286 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 28
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 21 more

Conditions: Healthy
Interventions: KBP-7072, Placebo; Drug · Other
Lead sponsor: KBP Biosciences; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Secaucus, New Jersey

Conditions: Healthy Participants
Interventions: TAK-418, TAK-418 Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Glendale, California

Conditions: Influenza Type A, Influenza Type B, Influenza
Interventions: SAB-176, Normal Saline; Biological · Other
Lead sponsor: SAb Biotherapeutics, Inc.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Diabetes type1
Interventions: AG019 - Low Dose, Teplizumab, Placebo-AG019, Placebo-Teplizumab, AG019 - High Dose; Biological · Drug
Lead sponsor: Precigen Actobio T1D, LLC; Industry
Eligibility: 12 Years to 40 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 15
States / cities: Birmingham, Alabama • San Francisco, California • Ventura, California + 12 more

Conditions: Healthy Volunteers
Interventions: MA-0211, Placebo; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 320 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: COVID-19
Interventions: VXA-CoV2-1.1-S, Placebo Tablets; Drug · Other
Lead sponsor: Vaxart; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 66 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 4
States / cities: Long Beach, California • Wichita, Kansas • Cleveland, Ohio + 1 more

Conditions: Autosomal Dominant Polycystic Kidney Disease
Interventions: AZD1613 - Part A, Placebo - Part A, AZD1613 - Part B, Placebo - Part B; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 8
States / cities: Birmingham, Alabama • Loma Linda, California • Jacksonville, Florida + 5 more

Conditions: Non-alcoholic Steatohepatitis (NASH)
Interventions: AZD2693, Placebo; Drug · Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 16
States / cities: Chula Vista, California • La Mesa, California • Montclair, California + 11 more

Search by objective public record fields.

A Study to Learn How Different Amounts of the Study Medicine Called PF-07976016 Are Tolerated and Act in The Body in Healthy Adults

Study to Evaluate the Safety, Pharmacokinetic, and Pharmacodynamic Effects of MY006 in Healthy Volunteers and Patients With Peanut Allergy

A Study to Investigate the Effect of Single Dose of AZD6094 (600 mg) on Cardiac Repolarization in Healthy Volunteers

Safety and Pharmacokinetics of VT-1598

AZD9773 Dose Escalation Study

Single and Multiple Ascending Doses of MEDI6570 in Subjects With Type 2 Diabetes Mellitus

A Study of PRA052 in Healthy Volunteers

Total Knee Arthroplasty Infiltration Study for Postoperative Analgesia

Sorafenib/Erlotinib Versus Erlotinib Alone in Previously Treated Advanced Non-Small-Cell Lung Cancer (NSCLC)

Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery

A Study of the Efficacy and Safety of Frespaciguat (MK-5475) in Participants With Pulmonary Arterial Hypertension (INSIGNIA-PAH: Phase 2/3 Study of an Inhaled sGC Stimulator in PAH) (MK-5475-007)

A Study of STP707 Administered by IV in Healthy Subjects

An Investigation of NNC 0151-0000-0000 in Subjects With Systemic Lupus Erythematosus (SLE)

Safety and Hemodynamic Effects and Pharmacokinetics of CXL-1020 in Patients With Stable Heart Failure

A First-in-Human Study of AV-001 in Healthy Subjects

A Study Evaluating the Efficacy and Safety of Vixarelimab in Participants With Idiopathic Pulmonary Fibrosis and in Participants With Systemic Sclerosis-Associated Interstitial Lung Disease

A Multiple Ascending Dose Study of KBP-7072 in Healthy Subjects

A Study to Evaluate Safety, Tolerability and Pharmacokinetics of Ascending Oral Single Dose of TAK-418 in Healthy Participants

Safety, Tolerability, and Pharmacokinetics of SAB-176 in Healthy Participants

A Study to Assess the Safety and Tolerability of Different Doses of AG019 Administered Alone or in Combination With Teplizumab in Participants With Recent-onset Diagnosed Type 1 Diabetes (T1D)

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MA-0211 in Healthy Adult Subjects Including a Food Effect Cohort

A Ph 2 Trial With an Oral Tableted COVID-19 Vaccine

Safety, Tolerability and Pharmacokinetics of AZD1613 in Adults With Autosomal Dominant Polycystic Kidney Disease

A Study to Assess Safety, Tolerability, PK and PD of AZD2693 in Non-alcoholic Steatohepatitis Patients